NCT03360721
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer No drug interventions treatment 2 active_not_recruiting NCT04514484
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV No drug interventions treatment 1 active_not_recruiting NCT03784677
A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors treatment 1 completed NCT03873805
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer treatment 1 active_not_recruiting NCT03503097
Genetic Testing for Men With Metastatic Prostate Cancer No drug interventions Not Available Not Available active_not_recruiting NCT04777071
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer diagnostic 2 recruiting NCT03999515
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer treatment 2 terminated NCT05113537
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer treatment 1 / 2 recruiting NCT04592237
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer treatment 2 active_not_recruiting NCT04585932
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study treatment 2 withdrawn NCT03581500
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer No drug interventions diagnostic 2 active_not_recruiting NCT03751436
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer treatment 1 completed NCT03649841
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer treatment 2 terminated NCT06205316
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma No drug interventions treatment 3 recruiting NCT03678025
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer treatment 3 recruiting NCT05691465
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells treatment 2 recruiting NCT05869682
Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy No drug interventions supportive_care 2 recruiting NCT05241860
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) No drug interventions treatment 2 active_not_recruiting NCT06173362
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer treatment 2 recruiting NCT04314401
National Cancer Institute "Cancer Moonshot Biobank" No drug interventions Not Available Not Available recruiting NCT05487846
Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation No drug interventions health_services_research Not Available not_yet_recruiting NCT04455750
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy treatment 3 active_not_recruiting NCT04447703
Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study No drug interventions health_services_research Not Available active_not_recruiting NCT06129851
Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer treatment 2 not_yet_recruiting NCT04693377
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial No drug interventions supportive_care Not Available recruiting NCT04616547
Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones No drug interventions treatment 2 terminated NCT03217747
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies treatment 1 / 2 active_not_recruiting NCT05445609
Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer No drug interventions treatment 2 suspended NCT04050215
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer No drug interventions diagnostic 2 completed NCT04388852
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers No drug interventions treatment 1 recruiting NCT05037500
Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer No drug interventions treatment 1 recruiting NCT03582475
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate No drug interventions treatment 1 completed NCT06094842
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer No drug interventions treatment 1 not_yet_recruiting NCT04071236
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy No drug interventions treatment 1 / 2 recruiting NCT04501913
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes No drug interventions Not Available Not Available active_not_recruiting NCT05168618
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial No drug interventions treatment 2 recruiting NCT05627219
Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network No drug interventions Not Available Not Available recruiting NCT03878524
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial No drug interventions treatment 1 terminated NCT05054296
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring No drug interventions supportive_care 2 recruiting NCT04927663
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression No drug interventions diagnostic 1 recruiting NCT04716725
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer No drug interventions diagnostic 2 active_not_recruiting NCT04754425
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer No drug interventions treatment 2 active_not_recruiting NCT04734730
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer No drug interventions treatment 2 recruiting NCT04976257
Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion No drug interventions treatment 0 completed NCT03218826
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery No drug interventions treatment 1 active_not_recruiting NCT05045066
Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients No drug interventions treatment 0 recruiting NCT03707574
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study No drug interventions Not Available Not Available active_not_recruiting NCT04471974
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer No drug interventions treatment 2 recruiting NCT04067960
Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer No drug interventions screening 0 completed NCT04550494
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations No drug interventions treatment 2 recruiting NCT05034562
Gallium-68 PSMA-11 PET in Participants With Prostate Cancer No drug interventions diagnostic 2 withdrawn NCT03821792
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer No drug interventions treatment 2 active_not_recruiting NCT03517969
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer No drug interventions treatment 2 active_not_recruiting NCT04190446
Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment No drug interventions treatment 2 active_not_recruiting NCT03204812
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer No drug interventions treatment 2 completed NCT03709550
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer No drug interventions treatment 1 / 2 withdrawn NCT04915508
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy No drug interventions treatment 2 recruiting